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Abstract 
 
Introduction: Humans genes mutations in altered social conditions through interaction with 
environmental factors and harmful habits become an individual risk factor.  
 
Objectives: To evaluate Angiotensin-Converting Enzyme (ACE) and nitrogen monoxide 
metabolites (NO/NO2-/NO3-) blood levels depending on I/D polymorphism of ACE gene (dbSNP 
id:rs4646994), 894T>G of Endothelial Nitric Oxide Synthase (eNOS, dbSNP id:rs1799983) in 
pathogenesis of left ventricular hypertrophy (LVH) in patients with Essential Arterial 
Hypertension (EAH).  
 
Methods: 120 screened patients with EAH I-III stages (48.3% – women, 51.7% – men, average 
age 52.9±9.24 years) and 40 healthy persons participated in prospective study. Alleles of 
polymorphic locus were studied by PCR method. Serum ACE level was detected by ELISA. 
Plasma NO metabolites levels were determined by colorimetric method. Structural myocardium 
changes – by EchoCG, ECG. Results analyzed according to the European guidelines ESC/ESH 
(2009). 
 
Results: D-allele presence (ACE) associated with high risk of LVH geometric patterns and 
higher level of ACE. Presence of TT-genotype of eNOS gene (ID/TT-haplotype) associated with 
lower levels of NO metabolites by 14.5% (р<0.05). Homozygous D-allele carriers (regardless of 
genotypes combination of eNOS gene – DD/TG, DD/GG haplotypes) have ACE concentration 
increased by 18.1% and 17.5%, accordingly (р<0.05). The absence of mutations in haplotypes 
(II/GG) is a protective factor against LVH (OR=0.13, p=0.047), with the lowest level of ACE, 
followed by higher concentration of NO metabolites (p<0.05). The combination of D+T allele in 
haplotypes (ID/TG, DD/TG ) increases the relative risk of LVH and EAH II and III in 1.19-2.25 
times (OR=4.75-13.5, p≤0.021-0.001), which is confirmed by severity of clinical course, and 
increased ACE serum level (DD/TG carriers). 
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Conclusion: Risk groups for eccentric or concentric LVH models are D-allele carriers (ACE 
gene) with highest ACE level and T-allele of eNOS gene with lower concentration of NO 
metabolites.  
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Background 
Single- or polynucleotide replacement in the chromosome loci of genes-candidates for Essential 
Arterial Hypertension (EAH) associates with activity of the renin-angiotensin-aldosterone 
(RAAS), or Nitric Oxide Synthase (NOS) systems. This may manifest phenotypically as their 
hemodynamic expression or early damage of corresponding target-organs.1,2 Interesting in this 
respect is the role of polymorphic markers of arterial hypertension (AH) candidate genes, which 
cover different parts of the system and tissue circulation regulation and proliferation of vascular 
smooth muscle cells and cardiomyocytes. These include genes of renin (R14+17G), 
angiotensinogen (AGT), angiotensin receptors (AGTR1, AGTR2), ACE and endothelial NOS 
(eNOS), endothelin-1 (BsiY1) and kallikrein (S1386A, A1789G), aldosterone (SYP11B2), β1-
adrenoceptor (ADRβ1), catecholamines metabolism enzymes genes, glucagon, II β-hydroxylase, 
genes associated with insulin resistance (PC-1 k121q, PPAR-g2), etc. The role of mutations in 
key genes encoding RAAS activity, NOS and sympathoadrenal systems, in pathogenesis of 
target-organ damaging in EAH patients, including left ventricle hypertrophy (LVH), is not fully 
explored, available results are contradictory and differ greatly between populations and ethnic 
groups, with significant racial differences.1,3 LVH develops in 60% patients with hypertension, 
determining the risk level of cardiovascular events (CVE).4,5 However, LVH is not only a result 
of the hemodynamic component of the RAAS, NO and the sympathetic-adrenal system activity. 
60% of LVH appear regardless of blood pressure (BP).6-9 Some molecular and cellular 
mechanisms of RAAS, NO-system participation in the progression of cardio-vascular diseases 
(CVD), EAH and LVH realization, mainly studied in experimental models in vitro, including the 
morphological level.6,7,10  
The aim of our research is to evaluate the blood levels of angiotensin-converting enzyme (ACE) 
and nitrogen monoxide metabolites (NO/NO2-/NO3-) depending on the I/D polymorphism of the 
ACE gene (dbSNP id: rs4646994), 894T>G polymorphism of Endothelial Nitric Oxide Synthase 
gene (eNOS, dbSNP id: rs1799983) and their role in the pathogenesis of LVH in patients with 
EAH. 
 
Methods  
Study was performed in compliance with the Council of Europe Convention on Human Rights 
and Biomedicine and recommendations of the Committee on Bioethics of the Ministry of Health 
of Ukraine. Research list and Informed Consent patients’ Form were approved by the 
Biomedical Ethics Commission of Bukovina State Medical University, Ministry of Health of 
Ukraine (Chernivtsi, Ukraine). All enrolled patients were under observation in the Regional 
Clinical Cardiology Dispensary or municipal ambulatory hospital №1, or under the supervision 
of family physicians in Chernivtsi city (Ukraine) from 2007 to 2012. Genetic research performed 
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in the laboratory of Medical Biology and Genetics Department of Bukovina State Medical 
University. 
The prospective study included 150 patients with EAH I-III stages of severity (WHO/ISH, 
2003), and moderate, high and very high CV risk (ESC/ESH 2009, 2010) with average office BP 
higher than 140/90 mm Hg measured according to the ESH and ESC requirements (2009). 
Duration of EAH varied from 2 to 28 years (mean 15.73 ± 8.02 years).  
After screening (matching inclusion/exclusion criteria) 120 EAH patients were selected for 
further examination. Groups’ stratification by target-organ damage, complications, and CV risk 
was performed according to the classifications of WHO, national and European Societies of 
Cardiology and Hypertension (ESC, ESH, 2009, 2010). 15 patients (12.5%) were with EAH I 
stage (st) and moderate CV risk, 72 (60.0%) – with EAH II st and high CV risk, 33 (27.5%) - 
with EAH III st, high and very high CV risk; 58 (48.3%) women and 62 (51.7%) men, mean age 
52.91±9.24 years, mean body weight 72.2±12.05 kg, height – 169.7±9.63 cm, body mass index 
(BMI) – 25.58±3.15 kg/m2, respectively. The control group included 40 practically healthy 
individuals of appropriate age and gender (p>0.05). 
Exclusion criteria were: symptomatic (secondary) hypertension, sub- and decompensate liver and 
kidney diseases, chronic heart failure (CHF) II class (NYHA) and higher, ejection fraction (EF) 
less than 45%, an acute coronary syndrome or stroke prior of 3 months, acute heart failure, 
diabetes mellitus type 1 (DM1), sub- and decompensated type 2 diabetes (DM2), mental 
disorders, corticosteroids administration, oral contraceptives, pregnancy and lactation period, 
acute inflammatory processes or exacerbation of chronic inflammatory processes regardless 
location. 
Office systolic and diastolic BP (SBP, DBP), heart rate (HR) were measured according to 
European4,5 and National11 guidelines. 24-hour blood pressure monitoring (ABPM) performed 
with "ABPE-02" ("SOLVAIG", Ukraine, France) and "ABPM" ("Meditech", Hungary) 
according to standard protocol (40-55 measures/day). Data analysis was performed with the 
devices’ software. BP results we described in previously published data.8 
LVH estimated using M- and B-modes of Echocardiography (SonoAce8000 SE, "Medison", 
Korea), analyzed standard linear indicators of structural and functional state of the left ventricle, 
including the LV geometry. Left ventricular mass (LVM) was evaluated according to the Penn 
Convention, LVM index (LVMI) was calculated as the LVM to body surface area (g/m2) ratio. 
LVH was evaluated according to the European Guidelines (ESH, ESC, 2009) criteria: LVMI in 
men ≥125 g/m2, in women ≥110 g/m2. According to LVMI and left ventricular relative wall 
thickness (RWT) the following geometric models of LV (ESH, ESC, 2009) were identified: 
normal LV geometry (LV NG), LV concentric remodeling (LV CR), eccentric LVH (LV EH), 
concentric LVH (LV CH). In addition, patients’ examination list included ECG in 12 standard 
leads, Ultrasonography of kidneys and abdominal organs, clinical and biochemical analysis, 
consultations by ophthalmologist, neurologist. 
The ACE level serum in 88 EAH patients was studied in enzyme immunoassay (ELISA) with 
"Quantikine®" (R&D Systems, Inc., USA) set of reagents. The nitrogen monoxide metabolites 
(NO2+NO3) concentration was determined in 30 EAH patients' plasma, stabilized with EDTA (1 
mg/ml), by colorimetric method with "Total NO/NO2-/NO3-" (RDS, UK) set of reagents after 
recovery of nitrate to nitrite by nitrate-reductase enzyme. 
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Genomic DNA was extracted from peripheral blood leukocytes using the "DNA-sorb-B" test 
system, with primers specific to the genes' alleles.12 Amplified polymorphic loci were detected 
by polymerase chain reaction (PCR) on "Amply-4L" device according to the manufacturer’s 
protocol. PCR restriction fragment visualization was performed according to previously 
described methods to determine the I/D polymorphism of the ACE gene13 and T894G 
polymorphism of the NOS gene.14 Alleles' discrimination of eNOS gene was performed by 
restriction endonuclease BanII (Eco241) ("Fermentas", USA), digested for 16 hours at 37°C. 
Amplified DNA fragments were separated by gel electrophoresis, stained with xylene zianol, 
visualized by transluminator in the presence of molecular mass ladder (100-1000 bp).9 
Statistical processing was performed with MS® Excel® 2003™, Primer of Biostatistics® 6.05 
and Statistica® 7.0 (StatSoft Inc., USA) software. Differences in continuous variables between 
cases and controls were analyzed using the unpaired Student’s t-test (distribution in 
Kolmogorov-Smirnov and W-Shapiro-Wilk test were close to normal) or Wilcoxon-Mann-
Whitney U-test; analysis of qualitative data (categorical variables) were assessed using the chi-
square test (χ2), incl. deviation from the Hardy-Weinberg equilibrium, comparison of allele 
frequencies with 1 degree of freedom (df), haplotypes and genotypes between the groups and the 
control with 2 df. The associations between alleles or genotypes, and LVH or EAH severity were 
tested using odds ratio (OR) with 95% confidence intervals (CI). The differences were 
considered significant at p<0.05. 
 
Results 
Level of nitric oxide metabolites (total NO/NO2-/NO3-) in plasma of patients decreased with 
increasing CV risk and severity of EAH, but significantly only in patients with EAH III st., high 
and very high CV risk versus (vs) EAH I st. and moderate CV risk by 21.9% (22.82±1.96 vs 
29.23±2.70 µmol/l, p<0.05). ACE concetration in serum reliably was higher in patients with 
target-organ damage, high and very high CV risk (EAH II and III stages) than in patients with 
moderate CV risk (EAH I st.) by 32.5% (33.10±5.07 vs 22.34±3.58 ng/ml, p=0.05) and by 
38.0% (36.03±4.90 vs  22.34±3.58 ng/ml, p=0.039), respectively. 
The distributions of all alleles and genotypes of analyzed genes were within the Hardy-Weinberg 
equilibrium. No changes of monoxide nitrogen metabolites were observed in dependence on 
ACE genotypes (table 1). The NO metabolites concentration was reliably lower in homozygous 
carriers of the mutant T-allele of eNOS gene than in patients with the G-allele (GG-and TG-
genotypes): by 20.6% (p<0.05) and 15.8% (p=0.05), respectively. ACE level was higher in D-
allele carriers of ACE gene (ID-and DD-genotypes) than in patients with the II genotype by 
21.6% (p=0.049) and 32.0% (p=0.028), respectively, and does not differ between genotypes of 
eNOS gene. 
LV NG was revealed in 10 (8.3%) patients with EAH I st; LV CR – in 15 (12.8%) patients: 5 
persons with EAG I st, 10 – with EAG II st; LV EH – in 38 (31.7%) EAH patients: 25 subjects 
with EAG II st, 13 – with EAH III st; LV CH - in 57 (47.5%) subjects: 37 individuals with EAH 
II st, 20 – with EAH III st, (χ2<1.0, p>0.05). The distribution of ventricular geometric patterns 
depending on alleles of the analyzed genes: LV EH and CH occurred more often in D-allele 
carriers (DD + ID-genotypes) of ACE gene (85.3% and 88.7% vs 58.3% cases of II-genotype 
carriers, p<0.001), in T-allele (TT + TG-genotypes) of eNOS gene (100.0% and 89.1% vs 63.8% 
International Journal of Collaborative Research on Internal Medicine & Public Health 
 
 
 
 
 
  
       Vol. 5 No. 3 (2013) 
172 
cases of GG-genotype carriers, p≤0.014-0.003). The D-allele of ACE gene and T-allele of eNOS 
gene were identified as "damaging, mutant" alleles.  
Analysis of possible genotypes combinations and distribution depending on the LV geometrical 
model is shown in table 2. The most frequent heterozygous combinations were ID/TG 
haplotypes – in 25.8% cases, and ID/GG, DD/TG – in 20.0% and 16.7%, respectively. The 
combination of homozygous “mutant” alleles of ACE gene and eNOS gene (D- and T-) was not 
detected. Genotypes combinations of DD/GG, II/TG and II/TG were distributed almost equally – 
11.7%, 10.8% and 7.5%, respectively (p>0.05). ID/TT, II/TT haplotypes were observed less 
often, in 5.8% and 1.7% cases, respectively. Comparative analysis of the LV geometric patterns 
frequencies showed that in II/GG haplotype carriers NG and LV CR were revealed more often 
than in patients with II/TG- (χ2=12.84, p<0.001), ID/TT- (χ2=7.65, p=0.006) and ID/GG-
haplotype (χ2=6.23, p=0.013). LV hypertrophic models (LV EH and LV CH) were observed 
more frequently in ID/TG-haplotype patients, than in ID/GG-haplotype carriers (χ2=6.70, 
p=0.01); in ID/TT-haplotype patients, than in II/TT patients (χ2=4.37, p=0.037) with borderline 
advantage in II/TG-haplotype EAH patients (χ2=3.76, p=0.052) (tab. 2). 
ACE and nitrogen monoxide metabolites content depending on genotypes combinations is shown 
in table 3. The level of NO2-/NO3- was lower by 14.5% in the ID/TT haplotype carriers than in 
those with II/GG combination (p<0.05). The ACE level in patients with II/GG-haplotype was 
significantly lower than in homozygous D-allele carriers of ACE gene (DD/TG and DD/GG-
combinations) by 18.1% and 17.5%, respectively (p<0.05). Presence of the TT-genotype of 
eNOS gene (including conjunction with unfavorable D-allele of ACE gene) is accompanied by a 
reliable decrease of nitric oxide plasma level. However, homozygous D-allele of ACE gene 
presence in EAH patients (regardless of the eNOS gene genotypes combination) is characterized 
by significantly higher concentration of ACE serum. 
The nitrogen monoxide metabolites content in plasma was significantly lower in patients with 
LV CH (mostly patients with EAH II and III stages, high and very high CV risk) than in patients 
with normal geometric model of left ventricle (EAH I st, moderate CV risk) by 23.5% (p<0.05 ). 
ACE level was significantly higher in LV CH patients than in LV NG and LV CR by 38.1% and 
24.6% (p<0.05), respectively (table 4). ACE concentration in patients with LV EH also prevailed 
such in patients with normal left ventricular geometry by 35.0% (p<0.05). 
Risk analysis of pathological changes in the geometric structure of the LV in patients with EAH 
based on haplotypes (table 5) showed significant increase in probability of hypertrophic left 
ventricle (LV EG and LV CH) in ID/TG and DD/TG haplotype carriers at 1.34 and 2.25 times 
(OR=5.98, and OR=13.5, respectively, χ2≤ 6.01-13.6, p≤0.015-0.001) at the lowest chances for 
normal geometry or concentric LV remodelling (OR=0.17 and OR=0.07, respectively, χ2≤4.68-
11.6, p≤0.031-0.001). The probability of favourable patterns of LV NG and LV CR in EAH 
patient with II/GG haplotype increases 2.53 times (OR=7.87, χ2=5.14, p=0.04), and the risk of 
LV EG and LV KG become the lowest in the population (OR=0.13, χ2=4.60, p=0.047). 
 
Discussion 
A number of studies have been devoted to the search of genetic markers that predispose to 
unfavorable clinical course of EAH with development of severe organ damage. However, the 
results are contradictory and vary depending on population or study.7,15-17 
International Journal of Collaborative Research on Internal Medicine & Public Health 
 
 
 
 
 
  
       Vol. 5 No. 3 (2013) 
173 
The main findings of our study showed association between I/D polymorphism of the ACE gene 
and 894T>G polymorphism of the eNOS gene and severity of EAH, presence and types of LVH: 
high-risk groups of LVH in patients with EAH are male carriers of DD-genotype and female 
carriers of D-allele of the ACE gene, and men with TT-genotype of eNOS gene. High-risk 
groups of the eccentric or concentric LVH models are D-allele carriers of ACE gene and the T-
allele carriers of eNOS gene. The combination of D and T "mutant" alleles in haplotypes (ID/TG 
and DD/TG options) increases the relative risk of LVH and EAH II and III stages 1.19-2.25 
times (OR=4.75-13, p≤0.021-0.001), correspondes with severity of clinical course of the disease, 
with the lowest chance for a normal geometry or concentric LV remodelling or milder EAH I st 
course (OR=0.07-0.17, p≤0.031-0.001). Our results suggest that D-allele and T-allele may 
contribute to unfavourable hypertrophic patterns of LV in hypertensive patients. We 
hypothesized that possible mechanism of LVH (LV CH and EH) realization in relation to D-
allele of ACE gene is associated with high ACE serum concentration, in TT-genotype carriers of 
eNOS gene – with low level of nitrogen monoxide metabolites. Our data is partly compatible 
with studies conducted in Japanese population (n=87)18, Uzbek population (n=172)19, Polish.20 
O. Hitoshi18 found reliable association of DD-genotype of ACE gene with concentric LVH, but 
not eccentric; with RWT, but not with LVMI. In addition, no association was found between 
ACE (I/D) genotypes and BP level. A. Ganau and R.B. Devereux21 suggested that concentric 
LVH is a result of pressure overload, whereas eccentric LVH is caused by concomitant 
hemodynamic volume and pressure overload, which associates partially with our findings. In 
other Japanese study22 no relationship was found between I/D polymorphism of the ACE gene 
and increased LVM in women with hypertension, whereas such association was observed in 
Japanese hypertensive men who had concentric LVH. 
At present, it is not clear whether there is a relationship between the 894T> allele or 894G allele 
of eNOS gene and LVH and EAH severity. Results of existing studies are controversial. Our 
findings of the mutant T-allele of eNOS gene relationship with the EAH severity are consistent 
with the Bogalusa Heart Study23, and the frequency of LVH – with the data of O.I. Yakovleva24. 
However, no relation is found between the size of LVH and geometric patterns.24,25 The 
relationship between plasma NO metabolites, serum ACE level and genotypes of the ACE I/D 
and eNOS 894T>G genes observed in our study are very similar to those reported for other 
Caucasian and non-Caucasion populations26-28 with limited information devoted to the 
haplotypes variants of ACE and eNOS genes distribution and association with ACE and NO 
levels, but not with LVH.29,30 
 
Limitations of the Study 
The present study was limited by a number of enrolled subjects. Furthermore, 105 of 120 
consecutive patients were previously pharmacologically treated for essential hypertension.  
  
Conclusion  
The results of our study provide evidence for associations between ACE (I/D), eNOS (894T>G) 
polymorphism and EAH and LVH patterns in North Bukovina (Western Ukraine) population. 
The presence of D-allele of ACE gene in hypertensive patients associates with higher frequency 
of left ventricular hypertrophic geometric patterns (LV EH and CH) and higher levels of serum 
ACE. Presence of TT-genotype of eNOS gene (including conjunction with unfavorable DD-
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genotype of ACE gene – ID/TT haplotype) is characterized by lower levels of total plasma NO 
metabolites. Homozygous D-allele of ACE gene (regardless of the genotypes combination of the 
eNOS gene – DD/TG and DD/GG) is accompanied by a significantly higher concentration of 
serum ACE. The combination of "mutant" D and T allele in haplotypes (ID/TG and DD/TG 
options) 1.19-2.25 times increases the relative risk of LVH and EAH II and III stages. The 
absence of mutations in haplotypes (II/GG variant) is a protective factor against LVH.  
Thus, the variations of ACE, I/D and eNOS 894T>G are additional individual predictive risk 
factors of target-organ damage (LVH) in hypertensive patients. In perspective, additional studies 
are needed to determine the pathogenetic mechanisms by which the ACE (I/D) and eNOS 
(894T>G) genotypes and haplotypes are linked to the LVH patterns, structural changes of the 
elastic type arteries in hypertensive patients, additional relations to RAAS and NO-system for 
early detection of target-organ damage.  
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Table 1: Angiotensin-converting enzyme level and monoxide nitrogen metabolites blood content 
in the hypertensive patients depending on the genotypes of ACE and eNOS genes 
 
Genes Genotypes, n=120 (%) # NO2-/NO3-, µmol/l ACE, ng/ml 
Control, n=40 35.60±3.45 20.53±4.26 
ACE 
(I/D) 
II, n=24 (20.0) 1 29.0±3.50 24.95±3.11  
DD, n=34 (28.3) 2 
24.58±2.91  
р<0.03 
36.70±4.20  
р<0.01 р1=0.028 
I/D, n=62 (51.7) 3 
27.6±3.67  
р<0.05 
31.81±2.16  
р=0.018 р1=0.049 
eNOS 
(T894G) 
GG, n=47 (39.2) 1 29.74±3.40 30.50±4.39 р<0.05 
TG, n=64 (53.3) 2 28.02±1.85  31.02±6.34 р<0.05 
TT, n=9 (7.5) 3 
23.60±2.20 р<0.01 
р1<0.05 р2=0.05 
32.97±5.56 р<0.05 
 
Notes:   
# – group supervision; 
p – difference compared to the control group; 
p1 – difference compared to the group #1 (homozygous patients II ACE, GG eNOS, 
respectively); 
p2 – difference compared to the group #2 (heterozygous patients ID, TG, respectively). 
 
 
Table 2: Geometric patterns of the left ventricle in patients with arterial hypertension depending 
on haplotypes of analyzed genes 
 
Left ventricle 
geometric pattern, n 
(%)  
Genotypes combination of ACE (I/D) and eNOS (894T>G) genes 
ІІ/TT, n=2 (%) II/TG, n=13 (%) II/GG, n=9 (%) 
LV NG, n=3  0 0 3 (33.3) 
LV CR, n=7  0 3 (23.1) 4 (44.4) 
LV EH, n=7  1 (50.0) 5 (38.5) 1 (11.1) 
LV CH, n=7  1 (50.0) 5 (38.5) 1 (11.1) 
 ID/TT, n=7 (%) ID/TG, n=31 (%) ID/GG, n=24 (%) 
LV NG, n=5  0 0 5 (20.8) 
LV CR, n=5  1 (14.3) 2 (6.5) 2 (8.3) 
LV EH, n=19 2 (28.6) 13 (41.9) 4 (16.7) 
LV CH, n=33 4 (57.1) 16 (51.6) 13 (54.2) 
 DD/TT, n=0 (%) DD/TG, n=20 (%) DD/GG, n=14(%) 
LV NG, n=2  – 1 (5.0) 1 (7.1) 
LV CR, n=3  – 1 (5.0) 2 (14.3) 
LV EH, n=12 – 7 (35.0) 5 (35.7) 
LV CH, n=17 – 11 (55.0) 6 (42.9) 
 
Notes:  
            LV NG – normal geometry of left ventricle;  
LV CR – concentric remodeling of left ventricle;  
LV EH – eccentric hypertrophy of left ventricle;  
LV CH – concentric hypertrophy of left ventricle; 
n (%) – number (%) of observed patients. 
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Table 3: Angiotensin-converting enzyme and nitrogen monoxide metabolites blood contents 
depending on haplotypes 
 
Genotypes combination of ACE (I/D) 
and eNOS (894T>G) genes 
ACE, ng/ml NO2-/NO3-, μmol/l 
ІІ/TT, n=2 28.84±4.74 26.05±2.85 
II/TG, n=13 27.90±3.72 28.61±2.67 
II/GG, n=9 27.72±2.01  29.37±1.25  
ID/TT, n=7  33.30±3.86 25.12±2.73 II/GG 
ID/TG, n=31  30.94±2.23 27.64±2.07 
ID/GG, n=24 31.18±4.25 28.50±2.18 
DD/TG, n=20 33.86±3.27 II/GG 26.30±4.38 
DD/GG, n=14 33.60±3.29 II/GG 27.16±3.15 
 
Notes: The probability difference regarding certain haplotype elevated to degree (p<0.05). 
 
 
 
Table 4: Angiotensin-converting enzyme and nitrogen monoxide metabolites blood contents 
depending on left ventricle geometric models 
 
LV Geometric Model NO2-/NO3-, µmol/l ACE, ng/ml 
LV NG, n=10 (8.3%) 30.12±2.08 22.08±2.46 
LV CR, n=15 (12.8%) 27.09±2.60 26.89±3.40 
LV EH, n=38 (31.7%) 23.95±4.33 33.97±5.03 р<0.05 
LV CH, n=57 (47.5%) 23.04±3.71 р<0.05 35.66±4.17 р,р1<0.05 
 
Notes:   
 LV NG – normal geometry of left ventricle;  
LV CR – concentric remodeling of left ventricle;  
LV EH – eccentric hypertrophy of left ventricle;  
LV CH – concentric hypertrophy of left ventricle; 
 p – difference compared to the patients with LV NG; 
 p1 – difference compared to the patients with LV CR; 
 p2 – difference compared to the patients with LV EH. 
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Table 5: Haplotypes of ACE and eNOS genes as risk factors for left ventricular geometry 
changes in patients with essential hypertension 
 
Data 
Potential risk factor 
II/TG II/GG ID/TG ID/GG DD/TG DD/GG 
E
c
c
e
n
tr
ic
 a
n
d
 c
o
n
c
e
n
tr
ic
  
L
V
H
  
 
ARI / 
ARR 
-0.09 0.47 -0.24 0.02 -0.50 -0.19 
RRI / 
RRR 
-0.14 0.68 -0.34 0.03 -1.25 -0.31 
RelR 1.14 0.32 1.34 0.97 2.25 1.31 
RR 1.31 0.29 3.65 0.95 6.88 1.99 
OR 1.56 0.13 5.98 0.91 13.5 2.44 
95% СІ RR  0.48-3.69 0.07-1.08 0.92-13.6 0.49-1.84 1.75-27.1 0.63-6.27 
95% СІ OR 0.35-7.80 0.02-0.91 1.49-25.1 0.28-2.92 2.75-66.3 0.59-10.2 
χ2 <1.0 4.60 6.01 <1.0 13.6 <1.0 
р >0.05 0.047 0.015 >0.05 <0.001 >0.05 
L
V
 N
o
r
m
a
l 
G
e
o
m
e
tr
y
 o
r 
C
o
n
c
e
n
tr
ic
 R
e
m
o
d
e
li
n
g
  
ARI / 
ARR 
0.09 -0.47 0.24 -0.02 0.50 0.19 
RRI / 
RRR 
0.28 -1.53 0.79 -0.07 0.83 0.46 
RelR 0.75 2.53 0.23 1.07 0.17 0.54 
RR 0.79 3.50 0.29 1.06 0.15 0.50 
OR 0.63 7.87 0.17 1.10 0.07 0.41 
95% СІ RR  0.27-2.19 0.90-13.24 0.06-1.09 0.54-2.05 0.04-0.57 0.16-1.58 
95% СІ OR 0.18-3.30 1.10-56.1 0.05-0.88 0.34-3.53 0.01-0.36 0.10-1.70 
χ2  <1.0 5.14 4.68 <1.0 11.6 <1.0 
р >0.05 0.04 0.031 >0.05 <0.001 >0.05 
 
Notes:  
ARI  / ARR– absolute risk increase / absolute risk reduction;  
RRI / RRR – relative risk increase / relative risk reduction;  
RelR – relative risk; RR – Risk Ratio;  
OR – Odds Ratio;  
95CІ RR,OR– confidence interval of Risk Ratio (RR), Odds Ratio (OR);   
LVH – left ventricle hypertrophy. 
 
